Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that positive
top-line results from the lead-in portion of its IGNITE 2 clinical
trial, a two-part Phase 3 clinical trial studying the efficacy and
safety of intravenous (IV) and oral formulations of eravacycline for the
treatment of complicated urinary tract infections (cUTI), support
advancement of the trial into its pivotal portion.
for Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data from Lead-in of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI Support Advancement to Pivotal Portion investment picks